Accessibility Menu

Hikma Pharmaceuticals Plc(FRA) H5P

Market Cap€3.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPON/A
5 YearN/A
1 YearN/A
1 MonthN/A
€18.59
-1.17%
-0.22Today

Hikma Pharmaceuticals Plc Financials at a Glance

Market Cap

€3.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

N/A

Net Income (TTM)

N/A

EPS (TTM)

€1.51

P/E Ratio

12.20

Dividend

€0.75

Beta (Volatility)

0.05 (Low)

Price

€18.59

Volume

0

Open

€18.82

Previous Close

€18.59

Daily Range

€18.59 - €18.82

52-Week Range

€13.80 - €21.40

Estimated Earnings Date

N/A

H5P News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Hikma Pharmaceuticals Plc

Hikma Pharmaceuticals Plc engages in developing, manufacturing, and marketing branded and non-branded generic pharmaceutical products. It operates through the following segments: Branded, Injectables, Generics, and Others. The Branded segment sells branded generics and in-licensed patented products in the Middle East and North Africa. The Injectables segment includes generic injectable products distributed globally and primarily used in hospitals. The Generics segment focuses on oral and other non-injectable generic products, and is sold in the U.S. retail market. The Others segment comprises of Arab Medical Containers Ltd., International Pharmaceutical Research Center Ltd., and the chemicals division of Hikma Pharmaceuticals Ltd. (Jordan). The company was founded by Samih Taleb Darwazah in 1978 and is headquartered in London, the United Kingdom.

Industry

Pharmaceuticals

Sector

Health Care

Employees

9,400

CEO

Riad Mishlawi

Website

www.hikma.com

H5P Financials

Key Financial Metrics (TTM)

Gross Margin

N/A

Operating Margin

N/A

Net Income Margin

N/A

Return on Equity

15.19%

Return on Capital

N/A

Return on Assets

N/A

Earnings Yield

8.20%

Dividend Yield

3.97%

Payout Ratio

N/A

Stock Overview

Market Cap

€3.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

207.23M

Volume

0

Avg. Volume

27.939

Financials (TTM)

Gross Profit

N/A

Operating Income

N/A

EBITDA

N/A

Operating Cash Flow

N/A

Capital Expenditure

N/A

Free Cash Flow

N/A

Cash & ST Invst.

N/A

Total Debt

N/A

Hikma Pharmaceuticals Plc Performance Analysis

Hikma Pharmaceuticals Plc annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 2,394,920,56110.9%
20232023-12-31EUR 2,659,290,08211.0%
20242024-12-31EUR 2,890,844,7098.7%
20252025-12-31EUR 2,967,451,2062.6%
Hikma Pharmaceuticals Plc annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 0.80-48.0%
20232023-12-31EUR 0.79-0.6%
20242024-12-31EUR 1.4987.9%
20252025-12-31EUR 1.607.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
CurrentYOY CHG

Revenue

N/A

N/A

Gross Profit

N/A

N/A

Gross Margin

N/A

N/A

Market Cap

€3.90BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

N/A

N/A

Net Income

N/A

N/A

EBITDA

N/A

N/A

Quarterly Fundamentals

Name
CurrentYOY CHG

Total Cash

N/A

N/A

Total Debt

N/A

N/A

Accounts Receivable

N/A

N/A

Inventory

N/A

N/A

Long Term Debt

N/A

N/A

Short Term Debt

N/A

N/A

Return on Assets

N/A

N/A

Return on Invested Capital

N/A

N/A

Free Cash Flow

N/A

N/A

Operating Cash Flow

N/A

N/A

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
^GSPCS&P 500
$7,684.24-0.00%
^DJIDJI
$53,254.61-0.01%
^IXICNASDAQ
$26,319.55-0.00%
BTCBitcoin
$78,890.00-0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
PCGPG&E
$13.27-0.20%
NVDANvidia
$220.78+0.01%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.97+0.11%
CNHCNH Industrial
$11.83+0.01%

Questions About H5P

What is the current price of Hikma Pharmaceuticals Plc?

Hikma Pharmaceuticals Plc is trading at €18.59 per share.

What is the 52-week range for Hikma Pharmaceuticals Plc?

Over the past 52 weeks, Hikma Pharmaceuticals Plc has traded between €13.80 and €21.40.

How much debt does Hikma Pharmaceuticals Plc have?

As of the most recent reporting period, Hikma Pharmaceuticals Plc reported total debt of €1.37B.

How much cash does Hikma Pharmaceuticals Plc have on hand?

Hikma Pharmaceuticals Plc reported €279.28M in cash and cash equivalents in its most recent financial results.

What is Hikma Pharmaceuticals Plc’s dividend yield?

Hikma Pharmaceuticals Plc currently has a dividend yield of 3.97%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services